All In Biotech

Drug Trial Radar · NCT04163185

Initiating Early Control of Migraine Pain and Associated Symptoms

A Randomized, Double-blind, Single-dose, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-07 (Meloxicam and Rizatriptan) for the Acute Treatment of Migraine in Adults

Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 302 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

302

Actual

Start

Oct 8, 2019

Primary completion

Mar 16, 2020

Study completion Mar 23, 2020

Sponsor

Lead sponsor
Axsome Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Nov 14, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

AXS-07 is an oral, investigational medicine consisting of MoSEIC meloxicam and rizatriptan, which is being developed for the acute treatment of migraine with or without aura in adults. AXS-07 tablets are formulated to provide an enhanced rate of absorption of meloxicam. This study is designed to evaluate the efficacy and safety of AXS-07 compared to placebo. This is a randomized, double-blind, single-dose, placebo-controlled trial. Subjects who successfully complete the screening period and continue to meet all entry criteria will be randomly assigned to take one dose of either AXS-07 or placebo upon the earliest onset of migraine pain.

Conditions

  • Migraine

Interventions

  • AXS-07 (MoSEIC meloxicam and rizatriptan)Drug

    AXS-07 tablet taken once upon the earliest onset of migraine pain.

  • PlaceboDrug

    Placebo tablet taken once upon the earliest onset of migraine pain.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects Achieving Headache Pain Freedom at Hour 2Time frame: Hour 2
  2. Percentage of Subjects With Absence of Most Bothersome Symptom at Hour 2Time frame: Hour 2

Locations

41 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Research Site

    Birmingham, Alabama

  • Clinical Research Site

    Birmingham, Alabama

  • Clinical Research Site

    Mobile, Alabama

  • Clinical Research Site

    Colton, California

  • Clinical Research Site

    Encino, California

  • Clinical Research Site

    Los Alamitos, California

  • Clinical Research Site

    Los Angeles, California

  • Clinical Research Site

    Redlands, California

  • Clinical Research Site

    Santa Monica, California

  • Clinical Research Site

    Spring Valley, California

  • Clinical Research Site

    Walnut Creek, California

  • Clinical Research Site

    Hallandale, Florida

  • Clinical Research Site

    Jacksonville, Florida

  • Clinical Research Site

    Lake City, Florida

  • Clinical Research Site

    Lake Worth, Florida

  • Clinical Research Site

    Ocoee, Florida

  • Clinical Research Site

    Orlando, Florida

  • Clinical Research Site

    Ormond Beach, Florida

  • Clinical Research Site

    South Miami, Florida

  • Clinical Research Site

    Sunrise, Florida

  • Clinical Research Site

    Tampa, Florida

  • Clinical Research Site

    Stockbridge, Georgia

  • Clinical Research Site

    Evanston, Illinois

  • Clinical Research Site

    Louisville, Kentucky

  • Clinical Research Site

    Boston, Massachusetts

  • Clinical Research Site

    Waltham, Massachusetts

  • Clinical Research Site

    Ann Arbor, Michigan

  • Clinical Research Site

    Springfield, Missouri

  • Clinical Research Site

    Albuquerque, New Mexico

  • Clinical Research Site

    Manlius, New York

  • Clinical Research Site

    Williamsville, New York

  • Clinical Research Site

    High Point, North Carolina

  • Clinical Research Site

    Oklahoma City, Oklahoma

  • Clinical Research Site

    Philadelphia, Pennsylvania

  • Clinical Research Site

    Charleston, South Carolina

  • Clinical Research Site

    Mt. Pleasant, South Carolina

  • Clinical Research Site

    Memphis, Tennessee

  • Clinical Research Site

    Nashville, Tennessee

  • Clinical Research Site

    Austin, Texas

  • Clinical Research Site

    Salt Lake City, Utah

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.